Gulf Pharmaceutical Industries P.S.C. (ADX: JULPHAR)
United Arab Emirates
· Delayed Price · Currency is AED 1.290
0.00 (0.00%)
Dec 20, 2024, 10:00 AM GST
ADX: JULPHAR Income Statement
Financials in millions AED. Fiscal year is January - December.
Millions AED. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | 2018 - 2014 |
|---|---|---|---|---|---|---|---|
Period Ending | Sep '24 Sep 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 | 2018 - 2014 |
| Revenue | 1,713 | 1,638 | 1,616 | 1,143 | 573 | 301.5 | Upgrade
|
| Revenue Growth (YoY) | 7.91% | 1.36% | 41.37% | 99.51% | 90.05% | -58.11% | Upgrade
|
| Cost of Revenue | 1,083 | 1,089 | 1,058 | 759.8 | 387.9 | 370 | Upgrade
|
| Gross Profit | 629.4 | 548.7 | 557.9 | 383.4 | 185.1 | -68.5 | Upgrade
|
| Selling, General & Admin | 604.9 | 591.4 | 596.3 | 451.9 | 397 | 400 | Upgrade
|
| Other Operating Expenses | -12.9 | -5 | -9.8 | -110 | -3.9 | -7.1 | Upgrade
|
| Operating Expenses | 592 | 586.4 | 586.5 | 341.9 | 393.1 | 392.9 | Upgrade
|
| Operating Income | 37.4 | -37.7 | -28.6 | 41.5 | -208 | -461.4 | Upgrade
|
| Interest Expense | -71.9 | -64 | -40.1 | -23.7 | -34 | -33.9 | Upgrade
|
| Interest & Investment Income | 4.3 | 6 | 3.6 | 2.4 | 2.1 | 1 | Upgrade
|
| Earnings From Equity Investments | - | - | - | -31.4 | 6.1 | -19.2 | Upgrade
|
| Currency Exchange Gain (Loss) | - | - | 0.2 | - | - | - | Upgrade
|
| EBT Excluding Unusual Items | -30.2 | -95.7 | -64.9 | -11.2 | -233.8 | -513.5 | Upgrade
|
| Gain (Loss) on Sale of Investments | 3.5 | 3.5 | 2 | -5.5 | -2 | 3.2 | Upgrade
|
| Asset Writedown | - | - | - | - | -37.7 | -1.7 | Upgrade
|
| Other Unusual Items | 6.7 | -1.6 | 29.5 | 59.3 | - | - | Upgrade
|
| Pretax Income | -20 | -93.8 | -33.4 | 42.6 | -273.5 | -512 | Upgrade
|
| Income Tax Expense | 1.9 | 9.2 | 2.8 | 1.1 | -1.8 | -2 | Upgrade
|
| Earnings From Continuing Operations | -21.9 | -103 | -36.2 | 41.5 | -271.7 | -510 | Upgrade
|
| Earnings From Discontinued Operations | 2.1 | 4.5 | 4.5 | 17.9 | -45.7 | -8.9 | Upgrade
|
| Net Income to Company | -19.8 | -98.5 | -31.7 | 59.4 | -317.4 | -518.9 | Upgrade
|
| Minority Interest in Earnings | -3.2 | -0.6 | 2.3 | 5 | 24.2 | 15.7 | Upgrade
|
| Net Income | -23 | -99.1 | -29.4 | 64.4 | -293.2 | -503.2 | Upgrade
|
| Net Income to Common | -23 | -99.1 | -29.4 | 64.4 | -293.2 | -503.2 | Upgrade
|
| Shares Outstanding (Basic) | 1,155 | 1,155 | 1,155 | 1,155 | 1,058 | 655 | Upgrade
|
| Shares Outstanding (Diluted) | 1,155 | 1,155 | 1,155 | 1,155 | 1,058 | 655 | Upgrade
|
| Shares Change (YoY) | - | - | - | 9.21% | 61.46% | - | Upgrade
|
| EPS (Basic) | -0.02 | -0.09 | -0.03 | 0.06 | -0.28 | -0.77 | Upgrade
|
| EPS (Diluted) | -0.02 | -0.09 | -0.03 | 0.06 | -0.28 | -0.77 | Upgrade
|
| Free Cash Flow | 208.2 | 70.1 | -44.4 | 1.8 | -184.3 | -119.3 | Upgrade
|
| Free Cash Flow Per Share | 0.18 | 0.06 | -0.04 | 0.00 | -0.17 | -0.18 | Upgrade
|
| Gross Margin | 36.75% | 33.50% | 34.52% | 33.54% | 32.30% | -22.72% | Upgrade
|
| Operating Margin | 2.18% | -2.30% | -1.77% | 3.63% | -36.30% | -153.03% | Upgrade
|
| Profit Margin | -1.34% | -6.05% | -1.82% | 5.63% | -51.17% | -166.90% | Upgrade
|
| Free Cash Flow Margin | 12.16% | 4.28% | -2.75% | 0.16% | -32.16% | -39.57% | Upgrade
|
| EBITDA | 134.8 | 61.7 | 66.5 | 128.5 | -109.7 | -374.6 | Upgrade
|
| EBITDA Margin | 7.87% | 3.77% | 4.11% | 11.24% | -19.14% | -124.25% | Upgrade
|
| D&A For EBITDA | 97.4 | 99.4 | 95.1 | 87 | 98.3 | 86.8 | Upgrade
|
| EBIT | 37.4 | -37.7 | -28.6 | 41.5 | -208 | -461.4 | Upgrade
|
| EBIT Margin | 2.18% | -2.30% | -1.77% | 3.63% | -36.30% | -153.03% | Upgrade
|
| Effective Tax Rate | - | - | - | 2.58% | - | - | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.